Atzumi for migraine: a new era of needle-free dihydroergotamine delivery.

Abstract

Migraine continues to affect a large portion of the population and remains difficult to treat effectively in many cases, especially when gastrointestinal symptoms interfere with medication absorption. Atzumi, a dihydroergotamine mesylate nasal powder, recently received U.S. Food and Drug Administration approval and represents a promising alternative. It uses a unique powder-based delivery system aimed at improving absorption and consistency of effect. Data from both early pharmacokinetic testing and a long-term safety study suggest that it works quickly and is generally well tolerated. Patients experienced meaningful relief, often without needing backup medications, and side effects were reported infrequently.